HOME > 의약학 > 내과학 > 대한소화기기능성질환·운동학회(구 대한소화관운동학회) > Gut and Liver
Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis
분야 의약학 > 내과학
저자 ( Mohamed Azab ) , ( Loomee Doo ) , ( Daniel H. Doo ) , ( Yousif Elmofti ) , ( Muazer Ahmed ) , ( John Jay Cadavona ) , ( Xibei B. Liu ) , ( Amaan Shafi ) , ( Moon Kyung Joo ) , ( Ji Won Yoo )
발행기관 대한소화기기능성질환·운동학회(구 대한소화관운동학회)
간행물정보 Gut and Liver 2017년, 제11권 제6호, 781~788쪽(총8쪽)
파일형식 19203040.pdf [다운로드 무료 PDF 뷰어]
판매가격 4,000원
적립금 120원 (구매자료 3% 적립)
이 자료를
논문의 미리보기 2페이지를 PDF파일로 제공합니다.
 
연관 논문
Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis
Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?
Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?
Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?
Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection
 
 
영문초록
Background/Aims: Although proton pump inhibitors (PPIs) have been widely used for the prevention and treatment of stress gastric ulcers in hospital settings, there are concerns that PPIs increase the risk of Clostridium difficile infection (CDI). However, little is known about the risk of CDI following PPI and histamine-2 receptor antagonist (H2RA) use. We evaluated the comparative hospital-acquired CDI occurrence risk associated with the concurrent use of PPIs versus H2RAs. Methods: A systematic search of PubMed, MEDLINE/Ovid, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Google Scholar through August 19, 2016, identified 12 studies that reported the hospital-acquired CDI occurrence following H2RA and PPI use for the prevention and treatment of stress gastric ulcers. Random-effects pooled odds ratios and 95% confidence intervals were estimated. Heterogeneity was measured using I2, and a meta-regression analysis was conducted. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to assess the overall quality of the evidence. Results: A total of 74,132 patients from 12 observational studies were analyzed. Compared to H2RAs, PPIs increased the risk of CDI by 38.6% (pooled odds ratio, 1.386; 95% confidence interval, 1.152 to 1.668; p=0.001; I2=42.81%). Subgroup analyses of the purpose of study medication use, study site, and study design confirmed the consistency of a greater CDI risk with PPIs than with H2RAs. The overall quality of evidence was rated as low. Conclusions: The use of PPIs for both the prevention and treatment of stress ulcers was associated with a 38.6% increased risk of hospital-acquired CDI occurrence compared to H2RA use. (Gut Liver 2017;11:781-788)
 
 
Clostridium; Stomach ulcer; Histamine antago-nists; Meta-analysis; Proton pump inhibitors
 
 
도움말
본 논문은 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
 
오늘 본 자료
오늘 본 자료가 없습니다.
장바구니 담은 자료
장바구니가 비어 있습니다.
이 간행물 인기자료
Case Report : Distal Cholangiocarci...
Case Report : Primary Rectal Amyloi...
Contrast Harmonic-Enhanced Endoscop...
Entecavir Reduced Serum Hepatitis B...
Utility of Elastography with Endosc...
이 간행물 신규자료
Serum MicroRNA Levels as a Noninvas...
Is the AIMS 65 Score Useful in Prep...
Comparison of the Hospital-Acquired...
Does Proton Pump Inhibitor Increase...
Serum MicroRNA Levels as a Noninvas...
저작권 정보
본 학술논문은 한국학술정보㈜ 각 학회간에 저작권 계약이 체결된 것으로 HAPPY학술이 제공하고 있습니다. 본 저작물을 불법적으로 이용시는 법적인 제재가 가해질 수 있습니다.
 
서비스이용약관 | 개인정보취급방침 | 사업자 정보확인 | E-mail 수집 거부 | 제휴 및 광고문의 | FAQ
이메일 무단 수집 거부
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나 그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며, 이를 위반시 정보통신망법에 의해 형사처벌됨을 유념하시기 바랍니다. [게시일 2003년 4월 2일]